Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 187

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

SRSF6-regulated alternative splicing that promotes tumour progression offers a therapy target for colorectal cancer

Wan, Ledong, Yu, Wenying, Shen, Enhui, Sun, Wenjie, Liu, Yuan, Kong, Jianlu, Wu, Yihua, Han, Fengyan, Zhang, Lei, Yu, Tianze, Zhou, Yuwei, Xie, Sunzhe, Xu, Enping, Zhang, Honghe, Lai, Maode · 2019 · Gut

Abstract

Objective: To investigate the molecular function of splicing factor SRSF6 in colorectal cancer (CRC) progression and discover candidate chemicals for cancer therapy through targeting SRSF6. Design: We performed comprehensive analysis for the expression of SRSF6 in 311 CRC samples, The Cancer Genome Atlas and Gene Expression Omnibus (GEO) database. Functional analysis of SRSF6 in CRC was performed in vitro and in vivo. SRSF6-regulated alternative splicing (AS) and its binding motif were identified by next-generation RNA-sequencing and RNA immunoprecipitation sequencing (RIP-seq), which was validated by gel shift and minigene reporter assay. ZO-1 exon23 AS was investigated to mediate the function of SRSF6 in vitro and in vivo. Based on the analysis of domain-specific role, SRSF6-targeted inhibitor was discovered de novo by virtual screening in 4855 FDA-approved drugs and its antitumour effects were evaluated in vitro and in vivo. Results: SRSF6 was frequently upregulated in CRC samples and associated with poor prognosis, which promoted proliferation and metastasis in vitro and in vivo. We identified SRSF6-regulated AS targets and discovered the SRSF6 binding motif. Particularly, SRSF6 regulates ZO-1 aberrant splicing to function as an oncogene by binding directly to its motif in the exon23. Based on the result that SRSF6 RRM2 domain plays key roles in regulating AS and biological function, indacaterol, a β2-adrenergic receptor agonist approved for chronic obstructive pulmonary disease treatment, is identified as the inhibitor of SRSF6 to suppress CRC tumourigenicity. Conclusions: SRSF6 functions the important roles in mediating CRC progression through regulating AS, and indacaterol is repositioned as an antitumour drug through targeting SRSF6. Accession numbers: The accession numbers for sequencing data are SRP111763 and SRP111797.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1136/gutjnl-2017-314983

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Cited by

See all 187

Metadata

Authors
Wan, L., Yu, W., Shen, E., Sun, W., Liu, Y., Kong, J., Wu, Y., Han, F., Zhang, L., Yu, T., Zhou, Y., Xie, S., Xu, E., Zhang, H., & Lai, M.
Venue
Gut
Publisher
BMJ
Published
2017-11-07
Volume
68
Issue
1
Pages
118-129
ISSN
  • 0017-5749 (ISSN-L)
  • 1468-3288
OpenAlex
W2767210015
Cited by
187
References
6
FWCI
5.05
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: SRSF6-regulated alternative splicing that promotes tumour progression offers a therapy target for colorectal cancer. https://app.cochat.ai/papers/10.1136/gutjnl-2017-314983
The paper
Wan, L., Yu, W., Shen, E., Sun, W., Liu, Y., Kong, J., Wu, Y., Han, F., Zhang, L., Yu, T., Zhou, Y., Xie, S., Xu, E., Zhang, H., & Lai, M. (2019). SRSF6-regulated alternative splicing that promotes tumour progression offers a therapy target for colorectal cancer. Gut. https://doi.org/10.1136/gutjnl-2017-314983

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.